CERVOMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.45 USD | -0.85% |
|
+0.49% | +220.45% |
| Apr. 08 | Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating | MT |
| Mar. 29 | CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 43.3 | 201.8 | - | - |
| Enterprise Value (EV) 1 | 43.3 | 156.5 | 88.9 | 138.3 |
| P/E ratio | -9.3 x | -17.8 x | -11 x | -8.25 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 6.06 x | 24 x | 31 x | - |
| EV / Revenue | 6.06 x | 18.6 x | 13.7 x | - |
| EV / EBITDA | - | -10.6 x | -2.41 x | -2.56 x |
| EV / FCF | - | -12.5 x | -2.74 x | -2.8 x |
| FCF Yield | - | -7.99% | -36.4% | -35.7% |
| Price to Book | - | 4.97 x | 2.87 x | 5.02 x |
| Nbr of stocks (in thousands) | 5,675 | 8,254 | - | - |
| Reference price 2 | 7.630 | 24.45 | 24.45 | 24.45 |
| Announcement Date | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 7.145 | 8.4 | 6.5 | - |
| EBITDA 1 | - | - | -14.7 | -36.9 | -54 |
| EBIT 1 | - | -7.813 | -12.95 | -26.25 | -39.5 |
| Operating Margin | - | -109.35% | -154.17% | -403.85% | - |
| Earnings before Tax (EBT) 1 | - | -2.172 | -12.5 | -26.15 | -39.4 |
| Net income 1 | -5.803 | -2.172 | -12.5 | -26.15 | -39.4 |
| Net margin | - | -30.4% | -148.81% | -402.31% | - |
| EPS 2 | -1.290 | -0.8200 | -1.370 | -2.215 | -2.965 |
| Free Cash Flow 1 | - | - | -12.5 | -32.4 | -49.4 |
| FCF margin | - | - | -148.81% | -498.46% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/13/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.526 | 2.491 | 2.35 | 2 | 2 | 2 |
| EBITDA 1 | - | - | -2.2 | -3.4 | -4.4 | -4.9 |
| EBIT 1 | -2.675 | -2.48 | -3.25 | -4 | -3.7 | -4.05 |
| Operating Margin | -175.25% | -99.59% | -138.3% | -200% | -185% | -202.5% |
| Earnings before Tax (EBT) 1 | 2.15 | -2.362 | -3.15 | -3.9 | -3.55 | -3.9 |
| Net income 1 | 2.15 | -2.362 | -3.15 | -3.9 | -3.55 | -3.9 |
| Net margin | 140.87% | -94.85% | -134.04% | -195% | -177.5% | -195% |
| EPS 2 | 0.6500 | -0.9500 | -0.3900 | -0.4200 | -0.3750 | -0.4050 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/13/23 | 3/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 45.3 | 113 | 63.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -12.5 | -32.4 | -49.4 |
| ROE (net income / shareholders' equity) | - | - | -56.4% | -46.9% | -60.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.920 | 8.530 | 4.870 |
| Cash Flow per Share 2 | - | - | -1.230 | -2.260 | -3.410 |
| Capex 1 | - | - | 1 | 2 | 2 |
| Capex / Sales | - | - | 11.9% | 30.77% | - |
| Announcement Date | 7/13/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
24.45
USD
Average target price
47.5
USD
Spread / Average Target
+94.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +220.45% | 204M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- CRVO Stock
- Financials CervoMed Inc.
